David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.
Pfizer Inc. announced on May 23 that David Simmons, president and general manager of emerging markets and established products, would be leaving the company to take over as chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a global contract research organization.
The company also said Olivier Brandicourt would take his place effective June 1, 2012. Brandicourt most recently was president and general manager of the primary care business unit
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
